Outcomes of transcorneal electrical stimulation therapy in the early stages of retinitis pigmentosa

Creative Commons License

Demir M. N., Acar U., Sobaci G., GÖKSÜLÜK D.

Turkish Journal of Medical Sciences, vol.52, no.3, pp.741-746, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 52 Issue: 3
  • Publication Date: 2022
  • Doi Number: 10.55730/1300-0144.5368
  • Journal Name: Turkish Journal of Medical Sciences
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.741-746
  • Keywords: Multifocal electroretinography, retinitis pigmentosa, tes therapy, transcorneal electrical stimulation, visual field, RETINAL GANGLION-CELLS, OPTIC NEUROPATHY, VISUAL-ACUITY, SURVIVAL, PHOTORECEPTORS, PROMOTES, TRIAL
  • Kayseri University Affiliated: No


© TÜBİTAK.Background/aim: To investigate the effect of transcorneal electrical stimulation (TES) therapy in patients with retinitis pigmentosa (RP). Materials and methods: We performed TES therapy in 21 patients with RP in 12 sessions with 1-week intervals. The following parameters obtained before and after the TES therapy were compared statistically; the best corrected visual acuity (BCVA, logMAR), Ishihara color vision level, multifocal electroretinography (mf-ERG) response, automated visual field (VF) outcome, and the 25-item low vision quality-of-life (LVQOL) questionnaire points. Results: The mean age of patients (6 females; 15 males) was 31.67 ± 9.80 years (20–50 years). While increases in BCVA level, color vision level, mf-ERG response in p1 amplitude of ring 1, and LVQOL questionnaire points were statistically significant, changes in VF test and other mf-ERG responses were not. Twenty of the patients (95.24%) stated that they were satisfied with the TES therapy. No considerable side effect was observed in any patient due to the therapy. Conclusion: The TES therapy may be an effective and safe treatment modality in slowing the RP progression, especially in the early stages of the disease. Longer-term follow-ups in larger patient populations are warranted.